Exploration of Medicine

Table 2. Age-standardized prevalence and incidence of type 2 diabetes mellitus (T2DM) by sex, with annual absolute change, 1990–2023.

Year	Prev. (M)	Δ Prev (M)	Prev. (F)	Δ Prev (F)	Inc. (M)	Δ Inc. (M)	Inc. (F)	Δ Inc. (F)
1990	2,817.8	—	2,709.1	—	163.5	—	145.1	—
1991	2,821.1	3.3	2,713.8	4.7	163.2	−0.3	145.2	0.1
1992	2,824.6	3.5	2,719.4	5.6	163	−0.2	145.3	0.1
1993	2,828.2	3.6	2,725.5	6.1	162.8	−0.2	145.5	0.2
1994	2,831.8	3.6	2,731.9	6.4	162.6	−0.2	145.6	0.1
1995	2,835.3	3.5	2,738.5	6.6	162.5	−0.1	145.8	0.2
1996	2,840.3	5	2,746.9	8.4	162.5	0	146	0.2
1997	2,847.7	7.4	2,758	11.1	162.7	0.2	146.3	0.3
1998	2,855.8	8.1	2,770.1	12.1	162.9	0.2	146.6	0.3
1999	2,862.9	7.1	2,781.6	11.5	163.1	0.2	146.9	0.3
2000	2,867.4	4.5	2,790.7	9.1	163.3	0.2	147.1	0.2
2001	2,865.1	−2.3	2,799.3	8.6	163.2	−0.1	147.2	0.1
2002	2,856.5	−8.6	2,809.3	10	162.7	−0.5	147.2	0
2003	2,845.4	−11.1	2,819.3	10	162.2	−0.5	147.2	0
2004	2,835.7	−9.7	2,827.5	8.2	161.8	−0.4	147.1	−0.1
2005	2,831.3	−4.4	2,832.2	4.7	161.9	0.1	147.1	0
2006	2,832.2	0.9	2,832.8	0.6	162.3	0.4	147.1	0
2007	2,835.6	3.4	2,830.3	−2.5	162.7	0.4	147.2	0.1
2008	2,840.7	5.1	2,826.4	−3.9	163.3	0.6	147.2	0
2009	2,846.9	6.2	2,822.7	−3.7	163.9	0.6	147.3	0.1
2010	2,853.6	6.7	2,820.5	−2.2	164.6	0.7	147.3	0
2011	2,861.3	7.7	2,818.5	−2.0	165.3	0.7	147.4	0.1
2012	2,870.8	9.5	2,815.6	−2.9	166.3	1	147.5	0.1
2013	2,881.5	10.7	2,813.6	−2.0	167.2	0.9	147.6	0.1
2014	2,892.7	11.2	2,814.2	0.6	168	0.8	147.7	0.1
2015	2,904.1	11.4	2,819.2	5	168.6	0.6	148	0.3
2016	2,918.9	14.8	2,830.8	11.6	169.2	0.6	148.4	0.4
2017	2,938.7	19.8	2,847.9	17.1	170.1	0.9	149.2	0.8
2018	2,959.6	20.9	2,867.1	19.2	171	0.9	150.1	0.9
2019	2,977.7	18.1	2,884.9	17.8	171.8	0.8	150.9	0.8
2020	2,989.3	11.6	2,897.6	12.7	172.2	0.4	151.5	0.6
2021	2,988.5	−0.8	2,905.4	7.8	171.7	−0.5	151.7	0.2
2022	2,986.4	−2.1	2,910.2	4.8	170.9	−0.8	151.9	0.2
2023	3,013.7	27.3	2,912.9	2.7	171.4	0.5	151.8	0.2

Return to article view

Δ indicates absolute annual change relative to the preceding year. M: male; F: female.

Supplementary materials

The supplementary tables for this article are available at: https://www.explorationpub.com/uploads/Article/file/1001416_sup_1.pdf.

Declarations

Acknowledgments

We are grateful for the collaboration between the National Data Management and Analytics Centre (NDMC) at the Ethiopian Public Health Institutes, the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, and the GBD Collaborators Network of Experts, and Hawassa University for the Ethiopia national and subnational burden of disease analysis.

Author contributions

KTB, WA, JB, and AM: Conceptualization. KTB, WA, JB, YAJ, SM, ST, A Walker, MN, A Worku, TM, AEA, AY: Data curation. KTB, WA, AEA: Formal analysis. WA, JB, YAJ, SM, ST, A Walker, MN, A Worku, TM, AEA, AY, CM: Investigation. KTB, A Walker, MN, AM, A Worku, TM, AEA, AY: Methodology. AM: Project administration. A Walker, MN, AM: Resources. KTB, A Walker, MN: Software. A Walker, MN, A Worku: Supervision. A Walker, MN, AM: Validation. KTB, CM: Visualization. KTB, A Worku: Writing—original draft. KTB. WA. JB. YAJ. SM. ST. A Walker. MN. A Worku. TM. AEA. AY. CM. AM: Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no competing interests.

Ethical approval

The manuscript used open-access GBD 2023 secondary data from the Institute for Health Metrics and Evaluation (IHME), University of Washington Health Data portal. As secondary, de-identified data were used, formal ethics approval was not required.

Consent to participate

As secondary, de-identified data were used, informed consent was not required.

Consent to publication

Not applicable.

Availability of data and materials

The datasets generated and/or analyzed during the study are available in the IHME Global Burden of Disease Data Exchange repository and can be accessed directly from: http://ghdx.healthdata.org/gbd-results-tool. The data will be made available, without undue reservation, to any qualified researcher.

Funding

The Bill and Melinda Gates Foundation funds national and subnational burden of disease studies (Grant Number: OPP1152504). The funder had no role in study design, data collection, analysis, interpretation, or writing of the report.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

IDF Diabetes Atlas 10th Edition 2021 [Internet]. International Diabetes Federation; c2026 [cited 2026 May 17]. Available from: https://idf.org/news-and-resources/resources/idf-diabetes-atlas-2021/

Ethiopian Public Health Institute (EPHI). Ethiopia STEPS Report on Risk Factors for Non-Communicable Diseases and Prevalence of Selected NCDs. Addis Ababa, Ethiopia: Ethiopian Public Health Institute; 2016.

GBD 2023 Disease and Injury and Risk Factor Collaborators. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406:1873–922. [DOI] [PubMed] [PMC]

Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, et al.; The GATHER Working Group. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. Lancet. 2016;388:e19–23. [DOI] [PubMed]

GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406:1811–72. [DOI] [PubMed] [PMC]

GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2133–61. [DOI] [PubMed] [PMC]

GBD 2019 Ethiopia Subnational-Level Disease Burden Initiative Collaborators. Progress in health among regions of Ethiopia, 1990-2019: a subnational country analysis for the Global Burden of Disease Study 2019. Lancet. 2022;399:1322–35. [DOI] [PubMed] [PMC]

Ethiopian Statistical Service (ESS). Inter-Censal Population Survey (ICPS) and Population Projection (2007–2037) [Internet]. Addis Ababa: ESS; c2026 [cited 2026 May 17]. Available from: https://ess.gov.et/download/icps-population-projection-2007-2037-produced-in-2012-2/

Mbanya JC, Motala AA, Sobngwi E, Assah FK, Enoru ST. Diabetes in sub-Saharan Africa. Lancet. 2010;375:2254–66. [DOI] [PubMed]

10.

Hall V, Thomsen RW, Henriksen O, Lohse N. Diabetes in Sub Saharan Africa 1999-2011: epidemiology and public health implications. A systematic review. BMC Public Health. 2011;11:564. [DOI] [PubMed] [PMC]

11.

Katte JC, Sibomana L, Hapunda G, Cikomola JC, Abidha CA. Diabetes in sub-Saharan Africa: what are the next steps? Lancet Diabetes Endocrinol. 2022;10:766–8. [DOI] [PubMed]

12.

Kengne AP, Amoah AG, Mbanya JC. Cardiovascular complications of diabetes mellitus in sub-Saharan Africa. Circulation. 2005;112:3592–601. [DOI] [PubMed]

13.

NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387:1513–30. [DOI] [PubMed] [PMC]

14.

Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88–98. [DOI] [PubMed]

15.

Abebe SM, Berhane Y, Worku A, Alemu S, Mesfin N. Level of sustained glycemic control and associated factors among patients with diabetes mellitus in Ethiopia: a hospital-based cross-sectional study. Diabetes Metab Syndr Obes. 2015;8:65–71. [DOI] [PubMed] [PMC]

16.

Berhe KK, Mselle LT, Gebru HB. The magnitude of chronic diabetes complications and its associated factors among diabetic patients attending the general hospitals in Tigray region, Northern Ethiopia. PLoS One. 2023;18:e0290240. [DOI] [PubMed] [PMC]

17.

Wei H, Liu S, Liao Y, Ma C, Wang D, Tong J, et al. A Systematic Review of the Medicinal Potential of Mulberry in Treating Diabetes Mellitus. Am J Chin Med. 2018;46:1743–70. [DOI] [PubMed]

18.

Xu R, Bai Y, Yang K, Chen G. Effects of green tea consumption on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Nutr Metab (Lond). 2020;17:56. [DOI] [PubMed] [PMC]

19.

Misganaw A, Haregu TN, Deribe K, Tessema GA, Deribew A, Melaku YA, et al. National mortality burden due to communicable, non-communicable, and other diseases in Ethiopia, 1990-2015: findings from the Global Burden of Disease Study 2015. Popul Health Metr. 2017;15:29. [DOI] [PubMed] [PMC]

20.

GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1603–58. [DOI] [PubMed] [PMC]

21.

GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1345–422. [DOI] [PubMed] [PMC]

22.

Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al.; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet. 2011;378:31–40. [DOI] [PubMed]

23.

Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020 [Internet]. WHO; c2026 [cited 2026 May 17]. Available from: https://www.who.int/publications/i/item/9789241506236

24.

Global report on diabetes [Internet]. WHO; c2026 [cited 2026 May 17]. Available from: https://www.who.int/publications/i/item/9789241565257

25.

Saving Lives, Spending Less: The Case for Investing in Noncommunicable Diseases [Internet]. Geneva: WHO; c2026 [cited 2026 May 17]. Available from: https://www.who.int/publications/i/item/9789240041059

26.

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–22. [DOI] [PubMed] [PMC]

27.

Political declaration of the third high-level meeting of the General Assembly on the prevention and control of non communicable diseases: Executive summary [Internet]. WHO; c2026 [cited 2026 May 17]. Available from: https://www.who.int/publications/m/item/political-declaration-of-the-third-high-level-meeting-of-the-general-assembly-on-the-prevention-and-control-of-non-communicable-diseases--executive-summary

28.

NCD Countdown 2030 collaborators. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet. 2018;392:1072–88. [DOI] [PubMed]